SYD-4228 by Byondis for Follicular Lymphoma: Likelihood of Approval

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

FDA approves first oral treatment for postpartum depression – Pharmaceutical Technology

The most common side effects associated with Zurzuvae are somnolence or sleepiness, dizziness, diarrhoea, fatigue, and urinary tract infection. Image Credit: Nicoleta Ionescu / Shutterstock.

August 7, 2023

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases – Biotech Investments

EQS-News: Formycon AG / Key word(s): Regulatory Approval/Miscellaneous Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory

September 28, 2024

Cannabis Stocks Are Rallying

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.